Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

Stopped early · Phase 2

Conditions studied: Lymphoma, Follicular

In brief

The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.

Key facts

Study ID

NCT00308087

Run by

Genzyme, a Sanofi Company

People needed

75

Starts

2006-05-01

Expected to finish

2009-06-01

Last updated by the study team

2013-12-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Huntsville, Alabama, United States
• Study site — Los Angeles, California, United States
• Study site — Montebello, California, United States
• Study site — Pleasant Hill, California, United States
• Study site — Gainesville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Ocala, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Elk Grove Village, Illinois, United States
• Study site — Springfield, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — New Albany, Indiana, United States
• Study site — Duluth, Minnesota, United States
• Study site — Fresh Meadows, New York, United States
• Study site — New York, New York, United States
• Study site — Columbus, Ohio, United States
• Study site — Hershey, Pennsylvania, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Houston, Texas, United States
• Study site — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.